CUBE vs LCTX · P/E 25, rev $1.07B vs rev $9.5M
CubeSmart (CUBE) versus Lineage Cell Therapeutics Inc (LCTX) — a side-by-side from cached financials, not a winner call.
CubeSmart (CUBE) is a reit - industrial company listed on US.
Lineage Cell Therapeutics Inc (LCTX) is a biotechnology company listed on US.
Latest reported CUBE revenue for 2024-12-31 was $1.07B. Net income was $391.9M. Revenue was up 1.5% from 2023-12-31 to 2024-12-31. CUBE currently screens at market cap $9.69B and trailing P/E 25.0.
Latest reported LCTX revenue for 2024-12-31 was $9.5M. Net income was -$18.6M. Revenue was up 354.9% from 2023-12-31 to 2024-12-31. LCTX currently screens at market cap $213.6M.
CUBE currently screens at market cap $9.69B and trailing P/E 25.0. LCTX currently screens at market cap $213.6M.
Not investment advice. Open the CUBE and LCTX stock pages for the full models.
Not investment advice.